Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles
Authors Rangger, Helbok A, Von Guggenberg E, Sosabowski J, Radolf, Prassl R, Andreae, Thurner, Haubner, Decristoforo C
Received 8 August 2012
Accepted for publication 21 September 2012
Published 27 November 2012 Volume 2012:7 Pages 5889—5900
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Christine Rangger,1 Anna Helbok,1 Elisabeth von Guggenberg,1 Jane Sosabowski,2 Thorsten Radolf,3 Ruth Prassl,4 Fritz Andreae,3 Gudrun C Thurner,5 Roland Haubner,1 Clemens Decristoforo1
1Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck, Austria; 2Center for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK; 3piCHEM Research and Development, Graz, 4Institute of Biophysics and Nanosystems Research, Austrian Academy of Sciences, Graz, 5Department of Radiology, Innsbruck Medical University, Innsbruck, Austria
Purpose: Liposomes have been proposed to be a means of selectively targeting cancer sites for diagnostic and therapeutic applications. The focus of this work was the evaluation of radiolabeled PEGylated liposomes derivatized with varying amounts of a cyclic arginyl–glycyl–aspartic acid (RGD) peptide. RGD peptides are known to bind to αvβ3 integrin receptors overexpressed during tumor-induced angiogenesis.
Methods: Several liposomal nanoparticles carrying the RGD peptide targeting sequence (RLPs) were synthesized using a combination of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, cholesterol, diethylenetriaminepentaacetic acid-derivatized lipids for radiolabeling, a polyethylene glycol (PEG) building block, and a lipid-based RGD building block. Relative amounts of RGD and PEG building blocks were varied. In vitro binding affinities were determined using isolated αvβ3 integrin receptors incubated with different concentrations of RLPs in competition with iodine-125-labeled cyclo-(-RGDyV-). Binding of the indium-111-labeled RLPs was also evaluated. Biodistribution and micro single photon emission computed tomography/computed tomography imaging studies were performed in nude mice using different tumor xenograft models.
Results: RLPs were labeled with indium-111 with high radiochemical yields. In vitro binding studies of RLPs with different RGD/PEG loading revealed good binding to isolated receptors, which was dependent on the extent of RGD and PEG loading. Binding increased with higher RGD loading, whereas reduced binding was found with higher PEG loading. Biodistribution showed increased circulating time for PEGylated RLPs, but no dependence on RGD loading. Both biodistribution and micro single photon emission computed tomography/computed tomography imaging studies revealed low, nonspecific tumor uptake values.
Conclusion: In this study, RLPs for targeting angiogenesis were described. Even though good binding to αvβ3 integrin receptors was found in vitro, the balance between PEGylation and RGD loading clearly requires optimization to achieve targeting in vivo. These data form the basis for future development and provide a platform for the investigation of multimodal approaches.
Keywords: liposomes, RGD peptides, αvβ3 integrin receptors, angiogenesis, tumor targeting
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]